Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13621MR)

This product GTTS-WQ13621MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13621MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6718MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ6467MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ3167MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ15584MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ13851MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ15766MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ6250MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ8326MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW